Briviact
Preclinical
UCBBriviact is one of 49 therapeutic programs targeting Epilepsy. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
48
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
84 competitors in Epilepsy
#DrugCompanyPhaseTrials
1Vimpat
UCBApproved
Fycompa
CCatalyst Biosciences
Approved
Diamox
TevaApproved
Briviact
UCBPhase 3
Dilantin
VViatris Specialty LLC
Approved
Zoloft
VViatris Specialty LLC
Approved
Ketalar
AAultman Health Foundation
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Coreg
Akero TherapeuticsApproved
Glucophage
EMD SeronoApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for Briviact. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company